Indaptus Therapeutics Announces Major Leadership and Board Changes

Indaptus Therapeutics ( (INDP) ) just unveiled an announcement.

On March 18, 2026, Indaptus Therapeutics underwent a major leadership reshuffle as directors Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes resigned, with Meckler and David Lazar also stepping down as co-chief executive officers, though Lazar stayed on the board while relinquishing the chairmanship and the company reported no disagreements underlying the departures. To stabilize governance, the board filled resulting committee vacancies by naming Matthew McMurdo to the Audit Committee, appointing Avraham Ben-Tzvi as chair of the Nominating Committee, assigning David Natan to the Compensation Committee and as Audit Committee chair, and installing Jerome Jabbour on the Nominating Committee and as chair of the Compensation Committee, while also appointing 39-year-old investment executive Junyi Dai as chairman of the board effective March 18 and as chief executive officer effective at the closing of the March 2026 securities purchase agreement, signaling a shift toward leadership with investment management and public company governance experience.

The most recent analyst rating on (INDP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.

Spark’s Take on INDP Stock

According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.

The score is primarily weighed down by weak financial performance (no revenue, widening losses, and heavy cash burn with a shrinking equity cushion), indicating ongoing financing/dilution risk. Technicals also remain bearish with price below key moving averages and negative MACD. Valuation metrics provide limited support due to negative earnings and no dividend, while recent corporate actions modestly help flexibility but reinforce capital-need concerns.

To see Spark’s full report on INDP stock, click here.

More about Indaptus Therapeutics

Indaptus Therapeutics operates in the biopharmaceutical industry, developing therapeutic candidates for serious diseases, with a focus on innovative immunotherapy-based treatments. The company is publicly listed and governed by a board and standard committee structure that oversees its strategic direction and corporate governance responsibilities.

Average Trading Volume: 174,482

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.88M

Find detailed analytics on INDP stock on TipRanks’ Stock Analysis page.